Log In
Print
BCIQ
Print
Print this Print this
 

avelumab (MSB0010718C)

Also known as: Anti-PD-L1

  Manage Alerts
Collapse Summary General Information
Company Merck KGaA
DescriptionHuman IgG1 mAb against programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274)
Molecular Target Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,850.0M

$850.0M

$2,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today